Sign in with Google. Opens in new tab

Pre-IPO Beijing Yuanxin Technology Group (PHIP Update) - Risk of Overvaluation and Poor Profit Model

477 Views15 Feb 2024 00:55
The dilemma of single revenue model and excessive reliance on drug sales is hard to overcome.Due to low gross margin, it's difficult to generate decent net profit margin. Pre-IPO valuation is too high
SUMMARY
(Sign Up to Access)
Full Insight
(Paid Plans Only, 4-minute read)
Discussions
(Paid Plans Only)
chart-bar
Price Chart(Sign Up to Access)
analytics-chart
x